Macugen FDA Approval History
FDA Approved: Yes (First approved December 17, 2004)
Brand name: Macugen
Generic name: pegaptanib
Dosage form: Ophthalmic Injection
Company: Eyetech / Pfizer Inc
Treatment for: Macular Degeneration
Macugen (pegaptanib) is a selective vascular endothelial growth factor (VEGF) antagonist indicated for the treatment of neovascular (wet) age-related macular degeneration (AMD), an eye disease associated with aging that destroys central vision.
Development Timeline for Macugen
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.